What this pack is
Catapres-TTS is the brand name in this record; clonidine is the generic name. Read both together with the dosage form (transdermal patch).
PACK CHECK · MARKET FIRST
Catapres-TTSGeneric nameclonidine
How this medicine works
The FDA label explains that clonidine stimulates brainstem alpha-adrenoreceptors, reduces central sympathetic outflow, and can lower peripheral resistance, heart rate and blood pressure. This helps explain why blood-pressure or heart-rate medicines need review together; it cannot calculate patch number, daily release, oral conversion or discontinuation.
Read source: United States ↗Historical public record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Catapres-TTS
- Generic name
- clonidine
- Dosage-form class
- Transdermal delivery system (patch)
- Route
- Transdermal
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A mg/24 h value describes the nominal delivery of this exact patch. Read it with total content, patch area and pack identity; it is not an individual patch-count or switching instruction.
The labelled amount delivered per day is not the total clonidine contained in the system. The separate adhesive cover contains no active medication and is not a medicine patch by itself.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (updated 6 Jan 2026; label revised Nov 2025)
Nominal clonidine delivery 0.1 mg per day for one week; 3.09 mg total per system; 4.33 cm²; four systems plus four adhesive covers per carton
- Product code
- NDC 82089-201-34
- Form and route
- CATAPRES-TTS-1 clonidine transdermal system · transdermal (label product-identity field)
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- clonidine (nominal delivery per day)
- 0.1 mgnominal delivery per day for one week; not an individual patch count, timing or switching instruction
- clonidine (total per transdermal system)
- 3.09 mgtotal amount in each system; not the amount delivered per day
- Package
- 4 systems per carton, plus 4 adhesive covers
- Patch area
- 4.33 cm²
- Labelled appearance
- tan patch · rectangular transdermal system, 4.33 cm²; adhesive cover contains no active medication
United States label · Current U.S. DailyMed public label (updated 6 Jan 2026; label revised Nov 2025)
Nominal clonidine delivery 0.2 mg per day for one week; 6.19 mg total per system; 8.67 cm²; four systems plus four adhesive covers per carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 82089-202-34
- Form and route
- CATAPRES-TTS-2 clonidine transdermal system · transdermal (label product-identity field)
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- clonidine (nominal delivery per day)
- 0.2 mgnominal delivery per day for one week; not an individual patch count, timing or switching instruction
- clonidine (total per transdermal system)
- 6.19 mgtotal amount in each system; not the amount delivered per day
- Package
- 4 systems per carton, plus 4 adhesive covers
- Patch area
- 8.67 cm²
- Labelled appearance
- tan patch · rectangular transdermal system, 8.67 cm²; adhesive cover contains no active medication
United States label · Current U.S. DailyMed public label (updated 6 Jan 2026; label revised Nov 2025)
Nominal clonidine delivery 0.3 mg per day for one week; 9.28 mg total per system; 13 cm²; four systems plus four adhesive covers per carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 82089-203-34
- Form and route
- CATAPRES-TTS-3 clonidine transdermal system · transdermal (label product-identity field)
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- clonidine (nominal delivery per day)
- 0.3 mgnominal delivery per day for one week; not an individual patch count, timing or switching instruction
- clonidine (total per transdermal system)
- 9.28 mgtotal amount in each system; not the amount delivered per day
- Package
- 4 systems per carton, plus 4 adhesive covers
- Patch area
- 13 cm²
- Labelled appearance
- tan patch · rectangular transdermal system, 13 cm²; adhesive cover contains no active medication
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
Catapres-TTS label reading: patch area, stated daily release and “adding or cutting” are not self-conversion rules
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the 2021 U.S. FDA label as a reading entry point. It helps check Catapres-TTS, clonidine transdermal system, the -1/-2/-3 identifiers, the weekly system and the labelled daily release; it does not decide patch number, replacement timing, conversion from oral medicine or discontinuation.
- Check Catapres-TTS, clonidine transdermal system, -1/-2/-3, weekly use and the 0.1/0.2/0.3 mg-per-day label information as one product-identity set. These identify the exact system; they are not self-conversion rules for adding, cutting, layering, replacing or changing to oral clonidine.
- The FDA label describes a multilayer system with a rate-controlling membrane. A loose-looking system, a change in appearance or a feeling that it is “not enough” cannot be used to infer cutting, enlarging the area, adding another system or changing use; have the exact package reviewed by a pharmacist or prescribing team.
- Sharing clonidine or a blood-pressure context does not prove that a patch, an oral form or another antihypertensive can be self-combined, substituted or suddenly stopped. With a beta blocker, certain calcium-channel blockers, sedating medicines, alcohol or other chronic-care products, have professionals review the complete list and actual products.
- For marked redness, blistering or widespread rash at the application site, dizziness, fainting, symptoms related to an abnormal heart rate, or uncertainty about a patch around MRI, surgery or another special situation, use timely local medical and professional support; this page does not provide an application, removal or discontinuation plan.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: Catapres-TTS public label ↗Historical public record · reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Catapres-TTS (clonidine). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Catapres-TTS is the brand in this record and clonidine is the active-ingredient name. Check both with the dosage form (Transdermal delivery system (patch)) and the market on the actual pack.
Read the labelled strength in context
A strength per patch or delivery rate describes the labelled transdermal-system identity. It is not an instruction to cut, combine, extend wear or alter replacement timing.
Keep the delivery system intact
For a patch or transdermal system, verify the exact strength, wear period and removal/replacement instructions in its current label. Do not cut, fold, alter or substitute a system on the basis of a similar-looking pack.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How clonidine works: it acts at brainstem alpha-adrenoreceptors and reduces sympathetic outflow
- “Reducing sympathetic outflow” is a mechanism, not a basis for treating an oral form and a patch with the same generic name as equivalent, or for deriving patch number, replacement timing or self-discontinuation. The exact product, prescription and current label must be checked together.
- This mechanism also helps explain why beta blockers, certain calcium-channel blockers and other products affecting heart rate or blood pressure cannot be judged by name alone for combination, substitution or alternation. Multiple medicines need item-by-item review by a pharmacist or prescribing team.
- Drowsiness, dizziness, symptoms related to a low heart rate, blood-pressure changes or a new skin reaction cannot be self-managed from a mechanism page. With an acute concern or a plan to change or remove any system, use timely local professional support rather than derive an action from pharmacology terms.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: Orange Book historical listing for Catapres-TTS (NDA 018891; product date 10 Oct 1984) ↗reviewed 2026-08-20
- FDA: Catapres-TTS supplemental-application materials ↗reviewed 2026-08-20
- FDA: Catapres-TTS public label ↗Historical public record · reviewed 2026-08-20
- FDA Drugs@FDA ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Catapres-TTSclonidine
This page links to public primary-source material for Catapres-TTS. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA Orange Book historical product date
An FDA Orange Book historical listing gives 10 Oct 1984 as the product date for Catapres-TTS under NDA 018891. This historical listing does not establish current labelling, strength, holder, supply or another-market status.
FDA: Orange Book historical listing for Catapres-TTS (NDA 018891; product date 10 Oct 1984) ↗FDA supplement-package entry
The linked FDA Catapres-TTS supplement package records NDA 018891-S15 and a 6 Sep 1996 entry. It does not represent initial approval or current product status.
FDA: Catapres-TTS supplement package ↗FDA transdermal-system label archive
The linked 2021 FDA Catapres-TTS label archive helps distinguish a transdermal system from oral or injectable presentations; the current label and strength require independent target-market review.
FDA: Catapres-TTS label archive ↗
MARKET SCOPE
Market-record boundary
United States
Public archive linkedOnly the FDA supplement package and label archive listed on this page are linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, patch strength, supply or sale-eligibility conclusion is inferred from U.S. historical material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Why cannot a patch be checked by generic name alone?
A transdermal system’s release design, strength, materials and label version each need separate review; a photo or generic name cannot establish equivalence with oral or injectable products.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.